SPG302 is being developed as a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive and…
WINNIPEG, MB / ACCESSWIRE / May 28, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused…
SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo")…
TORONTO, ON / ACCESSWIRE / May 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to…
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strainStudy initiated…
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic…
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to…
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in…
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…